Allogeneic Cell Therapy Market, 2023-2035 - Distribution by Type of Cell Therapy (Virus-Specific T-Cell, Stem Cell and Regulatory T-Cell), Source of Cell (Peripheral Blood, Bone Marrow, Umbilical Cord Blood, Adipose Tissue and Placenta), Target Indication (Bone Disorder, Critical Limb Ischemia, Crohn’s Disease, Diabetic Foot Ulcer, Graft versus Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndrome, Cytomegalovirus Infection, Others), Therapeutic Area (Oncological Disorders, Neurological Disorders, Musculoskeletal Disorders, Autoimmune / Inflammatory Disorders and Post-Transplant Infections), and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts
The global allogenic cell therapy market is expected to reach USD 2.74 billion by 2023 and is anticipated to grow at a CAGR of 14.5% during the forecast period 2023-2035
Allogeneic cell therapies signify prepared treatments sourced from donor tissues like cord blood or bone marrow. These are processed in laboratories, ready for immediate use or storage, eliminating the need for personalized manufacturing per patient. Their advantages lie in consistent quality ensured through rigorous processing controls, cost reduction from centralized manufacturing, and the flexibility to use the same or different donor for subsequent treatments. Additionally, advancements like CRISPR/Cas9 in gene editing have expanded their potential by enabling precise genetic modifications in donor cells, enhancing therapeutic properties, and reducing immune rejection risks.
Recent years have seen global regulatory approval for numerous allogeneic cell therapies across various conditions, including hematological malignancies (e.g., multiple myeloma, leukemia), post-transplant lymphoproliferative disorders (PTLD), neurological and musculoskeletal disorders, autoimmune, and inflammatory conditions. Notably, in December 2022, the European Commission endorsed Ebvallo, an allogeneic T-cell therapy by Atara Biotherapeutics, for treating Epstein-Barr virus positive post-transplant lymphoproliferative disease. Additionally, the FDA approved Osteocel® Plus, an allogeneic mesenchymal stem cell therapy developed by NuVasive, for treating degenerative disc disease. The collaborative efforts of industry and non-industry stakeholders, coupled with rising chronic disease prevalence and challenges in producing autologous cell therapies, are expected to drive substantial growth in the global allogeneic cell therapies market in the forecast period.
Report Coverage
Allogeneic cell therapies signify prepared treatments sourced from donor tissues like cord blood or bone marrow. These are processed in laboratories, ready for immediate use or storage, eliminating the need for personalized manufacturing per patient. Their advantages lie in consistent quality ensured through rigorous processing controls, cost reduction from centralized manufacturing, and the flexibility to use the same or different donor for subsequent treatments. Additionally, advancements like CRISPR/Cas9 in gene editing have expanded their potential by enabling precise genetic modifications in donor cells, enhancing therapeutic properties, and reducing immune rejection risks.
Recent years have seen global regulatory approval for numerous allogeneic cell therapies across various conditions, including hematological malignancies (e.g., multiple myeloma, leukemia), post-transplant lymphoproliferative disorders (PTLD), neurological and musculoskeletal disorders, autoimmune, and inflammatory conditions. Notably, in December 2022, the European Commission endorsed Ebvallo, an allogeneic T-cell therapy by Atara Biotherapeutics, for treating Epstein-Barr virus positive post-transplant lymphoproliferative disease. Additionally, the FDA approved Osteocel® Plus, an allogeneic mesenchymal stem cell therapy developed by NuVasive, for treating degenerative disc disease. The collaborative efforts of industry and non-industry stakeholders, coupled with rising chronic disease prevalence and challenges in producing autologous cell therapies, are expected to drive substantial growth in the global allogeneic cell therapies market in the forecast period.
Report Coverage
- The report conducts an analysis of the allogenic cell therapy market, focusing on cell therapy types, cell sources, target indications, therapeutic areas, and key geographical regions.
- It evaluates market growth factors such as drivers, restraints, opportunities, and challenges, influencing the industry landscape.
- The report examines potential advantages and hurdles within the market, offering insights into the competitive environment among leading market players.
- Revenue forecasts for market segments are provided concerning four major regions.
- A concise summary outlines the current status and expected evolution of the allogeneic cell therapy market in the mid to long term, drawing from comprehensive research insights.
- An inclusive introduction details allogeneic cell therapy, covering the manufacturing process, primary advantages, challenges, and recent advancements in this specialized market segment.
- A thorough evaluation considers various parameters like establishment year, company size in terms of workforce, headquarters location, development phase (preclinical, clinical, marketed), administration routes, cell therapy types, cell sources, dosing frequency, therapy types, target patient segments, indications, and therapeutic areas.
- Analysis of collaborations among stakeholders since 2019 encompasses research & development agreements, licensing agreements, product development, commercialization agreements, manufacturing/supply agreements, clinical trial agreements, mergers, acquisitions, and other relevant agreements.
- A detailed examination of investments in companies engaged in allogeneic cell therapies, including venture capital financing, IPOs, subsequent offerings, grants, and debt financing. Emphasis is on funding instances between 2019 and 2023, highlighting increased interest from venture capital and strategic investors.
- Scrutiny of completed and ongoing clinical trials related to allogeneic cell therapies, analyzing parameters such as registration year, trial status, phase, design, sponsor types, geographic distribution, and identification of the most active industry and non-industry participants.
- An insightful exploration identifies Key Opinion Leaders (KOLs) involved in allogeneic cell therapy trials, considering KOL types, qualifications, organizational affiliations, geographic locations, and target disease indications. Prominent KOLs are highlighted based on proprietary and third-party scoring criteria.
- AbbVie
- Academisch Medisch Centrum
- Acepodia
- Adaptimmune Therapeutics
- Adicet Bio
- Bristol Myers Squibb
- Duke University
1. PREFACE
1.1. Allogeneic Cell Therapy Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Overview of Allogeneic Cell Therapy
3.2. Manufacturing Process of Allogeneic Cell Therapy
3.3. Advantages Offered by Allogeneic Cell Therapy
3.4. Challenges Associated with Allogeneic Cell Therapy
3.5. Recent Developments in Allogeneic Cell Therapy Industry
3.6. Future Perspectives
4. MARKET LANDSCAPE
4.1. Allogeneic Cell Therapies: Market Landscape
4.1.1. Analysis by Phase of Development
4.1.2. Analysis by Route of Administration
4.1.3. Analysis by Type of Cell Therapy
4.1.4. Analysis by Source of Cell
4.1.5. Analysis by Dosing Frequency
4.1.6. Analysis by Type of Therapy
4.1.7. Analysis by Target Patient Segment
4.1.8. Analysis by Target Indication
4.1.9. Analysis by Therapeutic Area
4.2. Allogeneic Cell Therapies: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Most Active Players: Analysis by Number of Therapies
5. PARTNERSHIPS AND COLLABORATIONS
5.1. Chapter Overview
5.2. Partnership Models
5.3. Allogeneic Cell Therapies: Partnerships and Collaborations
5.3.1 Analysis by Year of Partnership
5.3.2. Analysis by Type of Partnership
5.3.3. Analysis by Year and Type of Partnership
5.3.4. Analysis by Type of Cell Therapy
5.3.5. Analysis by Therapeutic Area
5.3.6. Analysis by Type of Partner
5.3.7. Most Active Players: Analysis by Number of Partnerships
5.3.8. Analysis by Geography
5.3.8.1. Intercontinental and Intracontinental Deals
5.3.8.2. Local and International Deals
6. FUNDING AND INVESTMENTS
6.1. Chapter Overview
6.2. Types of Funding
6.3. Allogeneic Cell Therapies: Funding and Investments
6.3.1. Analysis by Year of Investment
6.3.2. Analysis by Amount Invested
6.3.3. Analysis by Type of Funding
6.3.4. Analysis of Amount Invested by Type of Funding
6.3.5. Analysis of Amount Invested by Year and Type of Funding
6.3.6. Analysis by Type of Investor
6.3.7. Analysis by Type of Therapy
6.3.8. Analysis by Geography
6.3.9. Leading Investors: Analysis by Number of Instances
6.3.10. Most Active Players: Analysis by Number of Instances
6.3.11. Most Active Players: Analysis by Amount Invested
7. CLINICAL TRIAL ANALYSIS
7.1. Analysis Methodology and Key Parameters
7.2. Allogeneic Cell Therapies: Clinical Trial Analysis
7.2.1. Analysis by Trial Registration Year
7.2.2. Analysis by Trial Status
7.2.3. Analysis by Trial Registration Year and Trial Status
7.2.4. Analysis by Trial Registration Year and Patients Enrolled
7.2.5. Analysis by Trial Status and Patients Enrolled
7.2.6. Analysis by Trial Phase
7.2.7. Analysis by Study Design
7.2.8. Analysis by Trial Status, Trial Phase and Geography
7.2.9. Analysis by Type of Sponsor
7.2.10. Most Active Industry Players: Analysis by Number of Trials
7.2.11. Most Active Non-Industry Players: Analysis by Number of Trials
7.2.12. Analysis by Geography
8. KEY OPINION LEADERS
8.1. Methodology and Key Parameters
8.2. Allogeneic Cell Therapies: Key Opinion Leaders (KOLs)
8.2.1. Analysis by Type of KOL
8.2.2. Analysis by Qualification
8.2.3. Analysis by Type of Organization
8.2.4. Analysis by Affiliated Organization
8.2.5. Analysis by Target Disease Indication
8.2.6. Analysis by Geographical Location of KOLs
8.2.7 Most Prominent KOLs: Peer Group 1 (Principal Investigators)
8.2.8 Most Prominent KOLs: Peer Group 2 (Study Directors)
8.2.9 Most Prominent KOLs: Peer Group 3 (Study Chair)
8.2.10. Most Prominent KOLs: Analysis by RA Score
9. MARKET FORECAST AND OPPORTUNITY ANALYSIS
9.1. Chapter Overview
9.2. Key Assumptions and Methodology
9.3. Global Allogeneic Cell Therapy Market, 2023-2035
9.3.1. Allogeneic Cell Therapy Market: Distribution by Type of Cell Therapy, 2023 and 2035
9.3.1.1. Allogeneic Cell Therapy Market for Stem Cell Therapies, 2023-2035
9.3.1.2. Allogeneic Cell Therapy Market for Virus-specific T-cell Therapies, 2023-2035
9.3.1.3. Allogeneic Cell Therapy Market for Regulatory T-cell Therapies, 2029-2035
9.3.2. Allogeneic Cell Therapy Market: Distribution by Source of Cell, 2023 and 2035
9.3.2.1. Allogeneic Cell Therapy Market for Bone Marrow / Matrix-derived Therapies, 2023-2035
9.3.2.2. Allogeneic Cell Therapy Market for Adipose Tissue-derived Therapies, 2023-2035
9.3.2.3. Allogeneic Cell Therapy Market for Peripheral Blood-derived Therapies, 2025-2035
9.3.2.4. Allogeneic Cell Therapy Market for Umbilical Cord-derived Therapies, 2023-2035
9.3.2.5. Allogeneic Cell Therapy Market for Placenta-derived Therapies, 2023-2035
9.3.2.6. Allogeneic Cell Therapy Market for Others, 2023-2035
9.3.3. Allogeneic Cell Therapy Market: Distribution by Target Indication, 2023 and 2035
9.3.3.1. Allogeneic Cell Therapy Market for Infectious Disease, 2023-2035
9.3.3.2. Allogeneic Cell Therapy Market for Chronic Heart Failure, 2023-2035
9.3.3.3. Allogeneic Cell Therapy Market for Crohn’s Disease 2023-2035
9.3.3.4. Allogeneic Cell Therapy Market for Ischemic Stroke, 2024-2035
9.3.3.5. Allogeneic Cell Therapy Market for Hematological Cancer, 2023-2035
9.3.3.6. Allogeneic Cell Therapy Market for Bone Diseases 2023-2035
9.3.3.7. Allogeneic Cell Therapy Market for Critical Limb Ischemia, 2023-2035
9.3.3.8. Allogeneic Cell Therapy Market for Graft versus Host Disease, 2023-2035
9.3.3.9. Allogeneic Cell Therapy Market for Duchenne Muscular Dystrophy, 2026-2035
9.3.3.10. Allogeneic Cell Therapy Market for Epidermolysis Bullosa, 2027-2035
9.3.3.11. Allogeneic Cell Therapy Market for Diabetic Foot Ulcer, 2023-2035
9.3.3.12. Allogeneic Cell Therapy Market for Others, 2023-2035
9.3.4. Allogeneic Cell Therapy Market: Distribution by Therapeutic Area, 2023 and 2035
9.3.4.1. Allogeneic Cell Therapy Market for Post-Transplant Infections, 2023-2035
9.3.4.2. Allogeneic Cell Therapy Market for Cardiovascular Disorders, 2023-2035
9.3.4.3. Allogeneic Cell Therapy Market for Autoimmune / Inflammatory Disorders, 2023-2035
9.3.4.4. Allogeneic Cell Therapy Market for Cerebrovascular Disorders, 2024-2035
9.3.4.5. Allogeneic Cell Therapy Market for Oncological Disorders, 2023-2035
9.3.4.6. Allogeneic Cell Therapy Market for Musculoskeletal Disorders, 2023-2035
9.3.4.7. Allogeneic Cell Therapy Market for Neurological Disorders, 2023-2035
9.3.4.8. Allogeneic Cell Therapy Market for Genetic Disorders, 2026-2035
9.3.4.8. Allogeneic Cell Therapy Market for Others, 2023-2035
9.3.5. Allogeneic Cell Therapy Market: Distribution by Key Geographical Regions, 2023 and 2035
9.3.5.1. Allogeneic Cell Therapy Market in North America, 2023-2035
9.3.5.1.1. Allogeneic Cell Therapy Market in the US, 2023-2035
9.3.5.1.2. Allogeneic Cell Therapy Market in Canada, 2024-2035
9.3.5.2. Allogeneic Cell Therapy Market in Europe, 2023-2035
9.3.5.2.1. Allogeneic Cell Therapy Market in the UK, 2023-2035
9.3.5.2.2. Allogeneic Cell Therapy Market in Germany, 2023-2035
9.3.5.2.3. Allogeneic Cell Therapy Market in France, 2023-2035
9.3.5.2.4. Allogeneic Cell Therapy Market in Italy, 2023-2035
9.3.5.2.5. Allogeneic Cell Therapy Market in Spain, 2023-2035
9.3.5.2.6. Allogeneic Cell Therapy Market in Rest of Europe, 2023-2035
9.3.5.3. Allogeneic Cell Therapy Market in Asia-Pacific and Rest of the World, 2023-2035
9.3.5.3.1. Allogeneic Cell Therapy Market in India, 2023-2035
9.3.5.3.2. Allogeneic Cell Therapy Market in Australia, 2026-2035
9.3.5.3.3. Allogeneic Cell Therapy Market in Taiwan, 2027-2035
9.3.5.3.3. Allogeneic Cell Therapy Market in Japan, 2023-2035
9.3.5.3.4. Allogeneic Cell Therapy Market in Korea, 2023-2035
9.3.5.3.5. Allogeneic Cell Therapy Market in Malaysia, 2023-2035
9.3.5.3.6. Allogeneic Cell Therapy Market in Israel, 2023-2035
9.4. Allogeneic Cell Therapy Market: Product-wise Sales Forecast, 2023-2035
9.4.1. Revascor / MPC-150-IM / Rexlemestrocel-L
9.4.1.1. Sales Forecast (USD Million)
9.4.1.2. Net Present Value
9.4.1.3. Value Creation Analysis
9.4.2. Alofisel / Darvadstrocel / Cx601
9.4.2.1. Sales Forecast (USD Million)
9.4.2.2. Net Present Value
9.4.2.3. Value Creation Analysis
9.4.3. MultiStem® (Athersys)
9.4.3.1. Sales Forecast (USD Million)
9.4.3.2. Net Present Value
9.4.3.3. Value Creation Analysis
9.4.4. Tab-cel® / tabelecleucel / ATA129
9.4.4.1. Sales Forecast (USD Million)
9.4.4.2. Net Present Value
9.4.4.3. Value Creation Analysis
9.4.5. MDR-101
9.4.5.1. Sales Forecast (USD Million)
9.4.5.2. Net Present Value
9.4.5.3. Value Creation Analysis
9.4.6. PLX-PAD
9.4.6.1. Sales Forecast (USD Million)
9.4.6.2. Net Present Value
9.4.6.3. Value Creation Analysis
9.4.7. OMISIRGE / Omidubicel-onlv
9.4.7.1. Sales Forecast (USD Million)
9.4.7.2. Net Present Value
9.4.7.3. Value Creation Analysis
9.4.8. Orca-T
9.4.8.1. Sales Forecast (USD Million)
9.4.8.2. Net Present Value
9.4.8.3. Value Creation Analysis
9.4.9. Ryoncil
9.4.9.1. Sales Forecast (USD Million)
9.4.9.2. Net Present Value
9.4.9.3. Value Creation Analysis
9.4.10. Stempeucel®
9.4.10.1. Sales Forecast (USD Million)
9.4.10.2. Net Present Value
9.4.10.3. Value Creation Analysis
9.4.11. Viralym-M / ALVR105 / Posoleucel
9.4.11.1. Sales Forecast (USD Million)
9.4.11.2. Net Present Value
9.4.11.3. Value Creation Analysis
9.4.12. Trinity Evolution®
9.4.12.1. Sales Forecast (USD Million)
9.4.12.2. Net Present Value
9.4.12.3. Value Creation Analysis
9.4.13. CAP-1002
9.4.13.1. Sales Forecast (USD Million)
9.4.13.2. Net Present Value
9.4.13.3. Value Creation Analysis
9.4.14. Osteocel® Plus
9.4.14.1. Sales Forecast (USD Million)
9.4.14.2. Net Present Value
9.4.14.3. Value Creation Analysis
9.4.15. MPC-06-ID / Rexlemestrocel-L
9.4.15.1. Sales Forecast (USD Million)
9.4.15.2. Net Present Value
9.4.15.3. Value Creation Analysis
9.4.16. AB-205 / E-CEL cells
9.4.16.1. Sales Forecast (USD Million)
9.4.16.2. Net Present Value
9.4.16.3. Value Creation Analysis
9.4.17. allo-APZ2-OTS
9.4.17.1. Sales Forecast (USD Million)
9.4.17.2. Net Present Value
9.4.17.3. Value Creation Analysis
9.4.18. Trinity ELITE
9.4.18.1. Sales Forecast (USD million)
9.4.18.2. Net Present Value
9.4.18.3. Value Creation Analysis
9.4.19. CYP-004
9.4.19.1. Sales Forecast (USD Million)
9.4.19.2. Net Present Value
9.4.19.3. Value Creation Analysis
9.4.20. Cytovir CMV T-cells
9.4.20.1. Sales Forecast (USD Million)
9.4.20.2. Net Present Value
9.4.20.3. Value Creation Analysis
9.4.21. CARTISTEM®
9.4.21.1. Sales Forecast (USD Million)
9.4.21.2. Net Present Value
9.4.21.3. Value Creation Analysis
9.4.22. Grafix®
9.4.22.1. Sales Forecast (USD Million)
9.4.22.2. Net Present Value
9.4.22.3. Value Creation Analysis
9.4.23. ELIXCYTE
9.4.23.1. Sales Forecast (USD Million)
9.4.23.2. Net Present Value
9.4.23.3. Value Creation Analysis
9.4.24. TEMCELL® HS
9.4.24.1. Sales Forecast (USD Million)
9.4.24.2. Net Present Value
9.4.24.3. Value Creation Analysis
9.4.25. ALLO-ASC-DFU
9.4.25.1. Sales Forecast (USD Million)
9.4.25.2. Net Present Value
9.4.25.3. Value Creation Analysis
10. EXECUTIVE INSIGHTS
10.1. Chapter Overview
10.2. Glycostem Therapeutics
10.2.1 Company Snapshot
10.2.2. Interview Transcript: Troels Jordansen (Chief Executive Officer)
10.3. Mesoblast
10.3.1 Company Snapshot
10.3.2. Interview Transcript
10.4. Triumvira Immunologics
10.4.1. Company Snapshot
10.5. Celyad Oncology
10.5.1. Company Snapshot
10.5.2. Interview Transcript
11. APPENDIX I: TABULATED DATA
12. APPENDIX I1: LIST OF COMPANIES AND ORGANIZATIONS
1.1. Allogeneic Cell Therapy Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Overview of Allogeneic Cell Therapy
3.2. Manufacturing Process of Allogeneic Cell Therapy
3.3. Advantages Offered by Allogeneic Cell Therapy
3.4. Challenges Associated with Allogeneic Cell Therapy
3.5. Recent Developments in Allogeneic Cell Therapy Industry
3.6. Future Perspectives
4. MARKET LANDSCAPE
4.1. Allogeneic Cell Therapies: Market Landscape
4.1.1. Analysis by Phase of Development
4.1.2. Analysis by Route of Administration
4.1.3. Analysis by Type of Cell Therapy
4.1.4. Analysis by Source of Cell
4.1.5. Analysis by Dosing Frequency
4.1.6. Analysis by Type of Therapy
4.1.7. Analysis by Target Patient Segment
4.1.8. Analysis by Target Indication
4.1.9. Analysis by Therapeutic Area
4.2. Allogeneic Cell Therapies: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Most Active Players: Analysis by Number of Therapies
5. PARTNERSHIPS AND COLLABORATIONS
5.1. Chapter Overview
5.2. Partnership Models
5.3. Allogeneic Cell Therapies: Partnerships and Collaborations
5.3.1 Analysis by Year of Partnership
5.3.2. Analysis by Type of Partnership
5.3.3. Analysis by Year and Type of Partnership
5.3.4. Analysis by Type of Cell Therapy
5.3.5. Analysis by Therapeutic Area
5.3.6. Analysis by Type of Partner
5.3.7. Most Active Players: Analysis by Number of Partnerships
5.3.8. Analysis by Geography
5.3.8.1. Intercontinental and Intracontinental Deals
5.3.8.2. Local and International Deals
6. FUNDING AND INVESTMENTS
6.1. Chapter Overview
6.2. Types of Funding
6.3. Allogeneic Cell Therapies: Funding and Investments
6.3.1. Analysis by Year of Investment
6.3.2. Analysis by Amount Invested
6.3.3. Analysis by Type of Funding
6.3.4. Analysis of Amount Invested by Type of Funding
6.3.5. Analysis of Amount Invested by Year and Type of Funding
6.3.6. Analysis by Type of Investor
6.3.7. Analysis by Type of Therapy
6.3.8. Analysis by Geography
6.3.9. Leading Investors: Analysis by Number of Instances
6.3.10. Most Active Players: Analysis by Number of Instances
6.3.11. Most Active Players: Analysis by Amount Invested
7. CLINICAL TRIAL ANALYSIS
7.1. Analysis Methodology and Key Parameters
7.2. Allogeneic Cell Therapies: Clinical Trial Analysis
7.2.1. Analysis by Trial Registration Year
7.2.2. Analysis by Trial Status
7.2.3. Analysis by Trial Registration Year and Trial Status
7.2.4. Analysis by Trial Registration Year and Patients Enrolled
7.2.5. Analysis by Trial Status and Patients Enrolled
7.2.6. Analysis by Trial Phase
7.2.7. Analysis by Study Design
7.2.8. Analysis by Trial Status, Trial Phase and Geography
7.2.9. Analysis by Type of Sponsor
7.2.10. Most Active Industry Players: Analysis by Number of Trials
7.2.11. Most Active Non-Industry Players: Analysis by Number of Trials
7.2.12. Analysis by Geography
8. KEY OPINION LEADERS
8.1. Methodology and Key Parameters
8.2. Allogeneic Cell Therapies: Key Opinion Leaders (KOLs)
8.2.1. Analysis by Type of KOL
8.2.2. Analysis by Qualification
8.2.3. Analysis by Type of Organization
8.2.4. Analysis by Affiliated Organization
8.2.5. Analysis by Target Disease Indication
8.2.6. Analysis by Geographical Location of KOLs
8.2.7 Most Prominent KOLs: Peer Group 1 (Principal Investigators)
8.2.8 Most Prominent KOLs: Peer Group 2 (Study Directors)
8.2.9 Most Prominent KOLs: Peer Group 3 (Study Chair)
8.2.10. Most Prominent KOLs: Analysis by RA Score
9. MARKET FORECAST AND OPPORTUNITY ANALYSIS
9.1. Chapter Overview
9.2. Key Assumptions and Methodology
9.3. Global Allogeneic Cell Therapy Market, 2023-2035
9.3.1. Allogeneic Cell Therapy Market: Distribution by Type of Cell Therapy, 2023 and 2035
9.3.1.1. Allogeneic Cell Therapy Market for Stem Cell Therapies, 2023-2035
9.3.1.2. Allogeneic Cell Therapy Market for Virus-specific T-cell Therapies, 2023-2035
9.3.1.3. Allogeneic Cell Therapy Market for Regulatory T-cell Therapies, 2029-2035
9.3.2. Allogeneic Cell Therapy Market: Distribution by Source of Cell, 2023 and 2035
9.3.2.1. Allogeneic Cell Therapy Market for Bone Marrow / Matrix-derived Therapies, 2023-2035
9.3.2.2. Allogeneic Cell Therapy Market for Adipose Tissue-derived Therapies, 2023-2035
9.3.2.3. Allogeneic Cell Therapy Market for Peripheral Blood-derived Therapies, 2025-2035
9.3.2.4. Allogeneic Cell Therapy Market for Umbilical Cord-derived Therapies, 2023-2035
9.3.2.5. Allogeneic Cell Therapy Market for Placenta-derived Therapies, 2023-2035
9.3.2.6. Allogeneic Cell Therapy Market for Others, 2023-2035
9.3.3. Allogeneic Cell Therapy Market: Distribution by Target Indication, 2023 and 2035
9.3.3.1. Allogeneic Cell Therapy Market for Infectious Disease, 2023-2035
9.3.3.2. Allogeneic Cell Therapy Market for Chronic Heart Failure, 2023-2035
9.3.3.3. Allogeneic Cell Therapy Market for Crohn’s Disease 2023-2035
9.3.3.4. Allogeneic Cell Therapy Market for Ischemic Stroke, 2024-2035
9.3.3.5. Allogeneic Cell Therapy Market for Hematological Cancer, 2023-2035
9.3.3.6. Allogeneic Cell Therapy Market for Bone Diseases 2023-2035
9.3.3.7. Allogeneic Cell Therapy Market for Critical Limb Ischemia, 2023-2035
9.3.3.8. Allogeneic Cell Therapy Market for Graft versus Host Disease, 2023-2035
9.3.3.9. Allogeneic Cell Therapy Market for Duchenne Muscular Dystrophy, 2026-2035
9.3.3.10. Allogeneic Cell Therapy Market for Epidermolysis Bullosa, 2027-2035
9.3.3.11. Allogeneic Cell Therapy Market for Diabetic Foot Ulcer, 2023-2035
9.3.3.12. Allogeneic Cell Therapy Market for Others, 2023-2035
9.3.4. Allogeneic Cell Therapy Market: Distribution by Therapeutic Area, 2023 and 2035
9.3.4.1. Allogeneic Cell Therapy Market for Post-Transplant Infections, 2023-2035
9.3.4.2. Allogeneic Cell Therapy Market for Cardiovascular Disorders, 2023-2035
9.3.4.3. Allogeneic Cell Therapy Market for Autoimmune / Inflammatory Disorders, 2023-2035
9.3.4.4. Allogeneic Cell Therapy Market for Cerebrovascular Disorders, 2024-2035
9.3.4.5. Allogeneic Cell Therapy Market for Oncological Disorders, 2023-2035
9.3.4.6. Allogeneic Cell Therapy Market for Musculoskeletal Disorders, 2023-2035
9.3.4.7. Allogeneic Cell Therapy Market for Neurological Disorders, 2023-2035
9.3.4.8. Allogeneic Cell Therapy Market for Genetic Disorders, 2026-2035
9.3.4.8. Allogeneic Cell Therapy Market for Others, 2023-2035
9.3.5. Allogeneic Cell Therapy Market: Distribution by Key Geographical Regions, 2023 and 2035
9.3.5.1. Allogeneic Cell Therapy Market in North America, 2023-2035
9.3.5.1.1. Allogeneic Cell Therapy Market in the US, 2023-2035
9.3.5.1.2. Allogeneic Cell Therapy Market in Canada, 2024-2035
9.3.5.2. Allogeneic Cell Therapy Market in Europe, 2023-2035
9.3.5.2.1. Allogeneic Cell Therapy Market in the UK, 2023-2035
9.3.5.2.2. Allogeneic Cell Therapy Market in Germany, 2023-2035
9.3.5.2.3. Allogeneic Cell Therapy Market in France, 2023-2035
9.3.5.2.4. Allogeneic Cell Therapy Market in Italy, 2023-2035
9.3.5.2.5. Allogeneic Cell Therapy Market in Spain, 2023-2035
9.3.5.2.6. Allogeneic Cell Therapy Market in Rest of Europe, 2023-2035
9.3.5.3. Allogeneic Cell Therapy Market in Asia-Pacific and Rest of the World, 2023-2035
9.3.5.3.1. Allogeneic Cell Therapy Market in India, 2023-2035
9.3.5.3.2. Allogeneic Cell Therapy Market in Australia, 2026-2035
9.3.5.3.3. Allogeneic Cell Therapy Market in Taiwan, 2027-2035
9.3.5.3.3. Allogeneic Cell Therapy Market in Japan, 2023-2035
9.3.5.3.4. Allogeneic Cell Therapy Market in Korea, 2023-2035
9.3.5.3.5. Allogeneic Cell Therapy Market in Malaysia, 2023-2035
9.3.5.3.6. Allogeneic Cell Therapy Market in Israel, 2023-2035
9.4. Allogeneic Cell Therapy Market: Product-wise Sales Forecast, 2023-2035
9.4.1. Revascor / MPC-150-IM / Rexlemestrocel-L
9.4.1.1. Sales Forecast (USD Million)
9.4.1.2. Net Present Value
9.4.1.3. Value Creation Analysis
9.4.2. Alofisel / Darvadstrocel / Cx601
9.4.2.1. Sales Forecast (USD Million)
9.4.2.2. Net Present Value
9.4.2.3. Value Creation Analysis
9.4.3. MultiStem® (Athersys)
9.4.3.1. Sales Forecast (USD Million)
9.4.3.2. Net Present Value
9.4.3.3. Value Creation Analysis
9.4.4. Tab-cel® / tabelecleucel / ATA129
9.4.4.1. Sales Forecast (USD Million)
9.4.4.2. Net Present Value
9.4.4.3. Value Creation Analysis
9.4.5. MDR-101
9.4.5.1. Sales Forecast (USD Million)
9.4.5.2. Net Present Value
9.4.5.3. Value Creation Analysis
9.4.6. PLX-PAD
9.4.6.1. Sales Forecast (USD Million)
9.4.6.2. Net Present Value
9.4.6.3. Value Creation Analysis
9.4.7. OMISIRGE / Omidubicel-onlv
9.4.7.1. Sales Forecast (USD Million)
9.4.7.2. Net Present Value
9.4.7.3. Value Creation Analysis
9.4.8. Orca-T
9.4.8.1. Sales Forecast (USD Million)
9.4.8.2. Net Present Value
9.4.8.3. Value Creation Analysis
9.4.9. Ryoncil
9.4.9.1. Sales Forecast (USD Million)
9.4.9.2. Net Present Value
9.4.9.3. Value Creation Analysis
9.4.10. Stempeucel®
9.4.10.1. Sales Forecast (USD Million)
9.4.10.2. Net Present Value
9.4.10.3. Value Creation Analysis
9.4.11. Viralym-M / ALVR105 / Posoleucel
9.4.11.1. Sales Forecast (USD Million)
9.4.11.2. Net Present Value
9.4.11.3. Value Creation Analysis
9.4.12. Trinity Evolution®
9.4.12.1. Sales Forecast (USD Million)
9.4.12.2. Net Present Value
9.4.12.3. Value Creation Analysis
9.4.13. CAP-1002
9.4.13.1. Sales Forecast (USD Million)
9.4.13.2. Net Present Value
9.4.13.3. Value Creation Analysis
9.4.14. Osteocel® Plus
9.4.14.1. Sales Forecast (USD Million)
9.4.14.2. Net Present Value
9.4.14.3. Value Creation Analysis
9.4.15. MPC-06-ID / Rexlemestrocel-L
9.4.15.1. Sales Forecast (USD Million)
9.4.15.2. Net Present Value
9.4.15.3. Value Creation Analysis
9.4.16. AB-205 / E-CEL cells
9.4.16.1. Sales Forecast (USD Million)
9.4.16.2. Net Present Value
9.4.16.3. Value Creation Analysis
9.4.17. allo-APZ2-OTS
9.4.17.1. Sales Forecast (USD Million)
9.4.17.2. Net Present Value
9.4.17.3. Value Creation Analysis
9.4.18. Trinity ELITE
9.4.18.1. Sales Forecast (USD million)
9.4.18.2. Net Present Value
9.4.18.3. Value Creation Analysis
9.4.19. CYP-004
9.4.19.1. Sales Forecast (USD Million)
9.4.19.2. Net Present Value
9.4.19.3. Value Creation Analysis
9.4.20. Cytovir CMV T-cells
9.4.20.1. Sales Forecast (USD Million)
9.4.20.2. Net Present Value
9.4.20.3. Value Creation Analysis
9.4.21. CARTISTEM®
9.4.21.1. Sales Forecast (USD Million)
9.4.21.2. Net Present Value
9.4.21.3. Value Creation Analysis
9.4.22. Grafix®
9.4.22.1. Sales Forecast (USD Million)
9.4.22.2. Net Present Value
9.4.22.3. Value Creation Analysis
9.4.23. ELIXCYTE
9.4.23.1. Sales Forecast (USD Million)
9.4.23.2. Net Present Value
9.4.23.3. Value Creation Analysis
9.4.24. TEMCELL® HS
9.4.24.1. Sales Forecast (USD Million)
9.4.24.2. Net Present Value
9.4.24.3. Value Creation Analysis
9.4.25. ALLO-ASC-DFU
9.4.25.1. Sales Forecast (USD Million)
9.4.25.2. Net Present Value
9.4.25.3. Value Creation Analysis
10. EXECUTIVE INSIGHTS
10.1. Chapter Overview
10.2. Glycostem Therapeutics
10.2.1 Company Snapshot
10.2.2. Interview Transcript: Troels Jordansen (Chief Executive Officer)
10.3. Mesoblast
10.3.1 Company Snapshot
10.3.2. Interview Transcript
10.4. Triumvira Immunologics
10.4.1. Company Snapshot
10.5. Celyad Oncology
10.5.1. Company Snapshot
10.5.2. Interview Transcript
11. APPENDIX I: TABULATED DATA
12. APPENDIX I1: LIST OF COMPANIES AND ORGANIZATIONS
